Literature DB >> 9447971

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

A S Lundberg1, R A Weinberg.   

Abstract

The retinoblastoma protein (pRb) acts to constrain the G1-S transition in mammalian cells. Phosphorylation of pRb in G1 inactivates its growth-inhibitory function, allowing for cell cycle progression. Although several cyclins and associated cyclin-dependent kinases (cdks) have been implicated in pRb phosphorylation, the precise mechanism by which pRb is phosphorylated in vivo remains unclear. By inhibiting selectively either cdk4/6 or cdk2, we show that endogenous D-type cyclins, acting with cdk4/6, are able to phosphorylate pRb only partially, a process that is likely to be completed by cyclin E-cdk2 complexes. Furthermore, cyclin E-cdk2 is unable to phosphorylate pRb in the absence of prior phosphorylation by cyclin D-cdk4/6 complexes. Complete phosphorylation of pRb, inactivation of E2F binding, and activation of E2F transcription occur only after sequential action of at least two distinct G1 cyclin kinase complexes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9447971      PMCID: PMC108786          DOI: 10.1128/MCB.18.2.753

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

1.  Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding.

Authors:  Y Qian; C Luckey; L Horton; M Esser; D J Templeton
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

3.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.

Authors:  P Whyte; K J Buchkovich; J M Horowitz; S H Friend; M Raybuck; R A Weinberg; E Harlow
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

4.  Physical interaction of the retinoblastoma protein with human D cyclins.

Authors:  S F Dowdy; P W Hinds; K Louie; S I Reed; A Arnold; R A Weinberg
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

5.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

6.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.

Authors:  D E Quelle; R A Ashmun; S A Shurtleff; J Y Kato; D Bar-Sagi; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

7.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

8.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins.

Authors:  M E Ewen; H K Sluss; C J Sherr; H Matsushime; J Kato; D M Livingston
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Association of human cyclin E with a periodic G1-S phase protein kinase.

Authors:  V Dulić; E Lees; S I Reed
Journal:  Science       Date:  1992-09-25       Impact factor: 47.728

10.  Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.

Authors:  M Ohtsubo; A M Theodoras; J Schumacher; J M Roberts; M Pagano
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

View more
  316 in total

1.  Accumulation of cyclin E is not a prerequisite for passage through the restriction point.

Authors:  S V Ekholm; P Zickert; S I Reed; A Zetterberg
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 2.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

3.  The kinetic origins of the restriction point in the mammalian cell cycle.

Authors:  B D Aguda; Y Tang
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

4.  Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases.

Authors:  S Wang; N Nath; A Minden; S Chellappan
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

5.  Hepatocyte growth factor releases mink epithelial cells from transforming growth factor beta1-induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2 activity.

Authors:  M Tsubari; J Taipale; E Tiihonen; J Keski-Oja; M Laiho
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

6.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

7.  Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells.

Authors:  D Chattopadhyay; M K Ghosh; A Mal; M L Harter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Reconstitution of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle.

Authors:  L Latella; A Sacco; D Pajalunga; M Tiainen; D Macera; M D'Angelo; A Felici; A Sacchi; M Crescenzi
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 9.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

10.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.